Scrip M&A Podcast with Cooley Attorneys Kevin Cooper and Bill Roegge.

Scrip Senior Writer Joseph Haas interviewed attorneys Kevin Cooper and Bill Roegge of Cooley LLP about recent events and trends in biopharmaceutical merger-and-acquisition activity. They discussed the current state of M&A after a busy conclusion to the first quarter and how that interplays with financing and partnering activity. In addition, Kevin offered tips for smaller companies to get good outcomes when dealing with large pharma firms, Bill talked about whether 2026 may be a year of competing bids in biopharma M&A and the discussion closed with a look at deals centered on platform technologies and their potential to replenish an acquirer's pipeline.